MedTrace Logo

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

NCT03729609 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2024-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) in routine clinical practice.

Conditions

  • Untreated CD30-Positive Hodgkin's Lymphoma

Interventions

DRUG

Brentuximab vedotin (Genetical Recombination)

Brentuximab vedotin Intravenous Infusion

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2023-09-27
Completion
2023-09-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03729609 on ClinicalTrials.gov